Bayer eyes capital raise as it grapples with Monsanto cases

Nicole DeFeudis

Editor

Bayer is asking shareholders to authorize a potential equity offer that would allow it to quickly raise billions of euros to deal with ongoing Monsanto …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bayer eyes capital raise as it grapples with Monsanto cases

Nicole DeFeudis

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Merck strikes deal for heart drug, worth up to $2B, with China’s Hengrui

Another immunology biotech emerges as Hillstar takes flight with $67M

WuXi Biologics’ licensing deals help offset Biosecure threat in the US

GSK to research whether shingles vaccine can cut dementia risk

Three major questions on pharma tariffs Trump claims are on the way

Ophthalmology startup Character Biosciences gets $93M for genetics-based approach

Bay­er eyes cap­i­tal raise as it grap­ples with Mon­san­to cas­es

Editor

Sign up to read this article for free.

more like this

Gondolabio

Palo Alto, CA, USA

Bayer eyes capital raise as it grapples with Monsanto cases